Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 9/2003

01-05-2003 | Adis Drug Profile

Panipenem/Betamipron

Authors: Karen L. Goa, Stuart Noble

Published in: Drugs | Issue 9/2003

Login to get access

Abstract

  • ▴ Panipenem is a parenteral carbapenem antibacterial agent with a broad spectrum of in vitro activity covering a wide range of Gram-negative and Gram-positive aerobic and anaerobic bacteria, including Streptococcus pneumoniae and species producing β-lactamases.
  • ▴ Panipenem is coadministered with betamipron to inhibit panipenem uptake into the renal tubule and prevent nephrotoxicity.
  • ▴ In large, randomised clinical trials, panipenem/ betamipron demonstrated good clinical and bacteriological efficacy (similar to that of imipenem/cilastatin) in adults with respiratory tract or urinary tract infections.
  • ▴ Panipenem/betamipron was also effective in adults with surgical or gynaecological infections, and in paediatric patients with respiratory tract and urinary tract infections in noncomparative trials.
  • ▴ In small trials in elderly patients reported as abstracts, panipenem/betamipron demonstrated clinical efficacy similar to intravenous piperacillin and greater than oral ofloxacin in urinary tract infections. Elderly patients with respiratory tract infections also responded to therapy.
  • ▴ Panipenem/betamipron is well tolerated with few adverse events reported in clinical trials, most commonly elevated serum levels of hepatic transaminases and eosinophils, rash and diarrhoea.
Footnotes
1
Use of trade name is for identification purposes only and does not imply product endorsement.
 
Literature
1.
Kawamoto I. 1beta-Methylcarbapenem antibiotics. Drags Future 1998; 23(2): 181–9CrossRef
2.
Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to pencillin-binding proteins, and stability to hydrolysis by β-lactamases. J Antimicrob Chemother 1995; 35: 75–84PubMedCrossRef
3.
Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996 Jan; 51(1): 99–136PubMedCrossRef
4.
5.
Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs 2000 Mar; 59: 653–80PubMedCrossRef
6.
Hikida M, Kawashima K, Yoshida M, et al. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother 1992 Aug; 30(2): 129–34PubMedCrossRef
7.
Panipenem/betamipron (Carbenin®) prescribing information. Sankyo Co., Ltd. 2001 Jul
8.
Hirouchi Y, Naganuma H, Kawahara Y, et al. Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Jpn J Pharmacol 1994 Sep; 66(1): 1–6PubMedCrossRef
9.
Naganuma H, Tokiwa H, Hirouchi Y, et al. Nephroprotective effect and its mechanism of betamipron (1) — relationships of renal transport [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 166–77
10.
Enomoto A, Takeda M, Shimoda M, et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 2002; 301(3): 797PubMedCrossRef
11.
Miyadera T, Sugimura Y, Oida S, et al. CS-976 (Panipenem/ Betamipron), a new carbapenem antibiotic. Sankyo Kenky-usho Nempo 1991; 43(3): 1–73
12.
Japanese Society of Chemotherapy. Committee for Revision of IC Determination Method. Breakpoint of antimicrobials for the treatment of respiratory tract infections and sepsis, supplement of new and existing antimicrobials [in Japanese]. Jpn J Chemother 1997 Sep; 45(9): 757–61
13.
Inoue K, Hamana Y, Mitsuhashi S. Antibacterial activity of panipenem, a new carbapenem antibiotic [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 1–13
14.
Higa F, Irabu Y, Fukuhara H, et al. Laboratory and clinical studies on panipenem/betamipron [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 449–54
15.
Goto Y, Ichimiya T, Ikuta M, et al. In vitro antibacterial activity of panipenem/betamipron, a carbapenem antibiotic, and its clinical study in respiratory airway infections [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 441–8
16.
Goto T, Makinose S, Kawahara M, et al. Antimicrobial activity and clinical evaluation of panipenem/betamipron in urinary tract infections [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 512–20
17.
Nomura S, Nagayama A. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections. J Chemother 2002 Apr; 14(2): 155–60PubMed
18.
Ohishi A, Takita M, Suzuki E, et al. Basic and clinical studies on panipenem/betamipron [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 339–49
19.
Furugo I, Takii M, Ueda M, et al. Microbiological and clinical studies of Haemophilus influenzae isolated at Kitakyushu Municipal Medical Center from 1996 through 1999 [in Japanese]. Jpn J Antibiot 2002 Jun; 55(3): 302–10PubMed
20.
Matsuo Y. In vitro susceptibilities to 23 antimicrobial agents of Haemophilus influenzae from pediatric patients in Japan. Kurame Med J 2000; 47(3): 205–10CrossRef
21.
Miyazaki S, Fujikawa T, Kanazawa K, et al. In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including beta-lactamase-negative ampicillin-resistant strains. J Antimicrob Chemother 2001 Nov; 48(5): 723–6PubMedCrossRef
22.
Watanabe A, Tokue Y, Takahashi H, et al. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother 2001 Dec; 7(4): 267–71PubMedCrossRef
23.
Hikida M, Terashima S, Sato Y, et al. Comparative antibacterial activity of carbapenems against P. aeruginosa (1) [in Japanese]. Jpn J Antibiot 2001 Nov; 54(11): 571–9PubMed
24.
Kato K, Iwai S, Kumasaka K, et al. Survey of antibiotic resistance in Pseudomonas aeruginosa by The Tokyo Johoku Association of Pseudomonas Studies. J Infect Chemother 2001 Dec; 7(4): 258–62PubMedCrossRef
25.
Fukuoka T, Ohya S, Narita T, et al. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 1993 Feb; 37(2): 322–7PubMedCrossRef
26.
Fukuoka T, Masuda N, Takenouchi T, et al. Increase in susceptibility of Pseudomonas aeruginosa to carbapenem antibiotics in low-amino-acid media. Antimicrob Agents Chemother 1991 Mar; 35: 529–32PubMedCrossRef
27.
Ishii C, Kakuta M, Abe T, et al. Rapid bactericidal activities of carbapenems against Pseudomonas aeruginosa in simulating human plasma concentrations [in Japanese]. Jpn J Antibiot 2002 Apr; 55(2): 187–95PubMed
28.
Nagai K, Matsuo Y, Tsumura N, et al. Antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae in south-western Japan and correlation of penicillin-binding protein 2b and 2x mutations in susceptibilities of penicillin G and cefotaxime. Diagn Microbiol Infect Dis 2000 Jun; 37(2): 107–13PubMedCrossRef
29.
Fukuoka T, Inoue H, Abe T, et al. In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae [in Japanese]. Jpn J Antibiot 2001 Jul; 54(7): 365–71PubMed
30.
Yonezu S, Yasunaga K, Ueda Y. Laboratory and clinical studies on panipenem/betamipron [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 385–93
31.
Ishihara S, Yasuda M, Tada K, et al. Clinical studies and antibiotic sensitivities of Enterococcus faecalis isolated from complicated urinary tract infection [in Japanese]. Jpn J Chemother 1995 Apr; 43: 451–6
32.
Hayashi I, Onuma K, Hasuike M. Panipenem/betamipron: antibacterial activity against Staphylococcus aureus and clinical efficacy in respiratory tract infection [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 333–8
33.
Utsui Y, Ohya S, Domon H, et al. Microbiological evaluation of panipenem/betamipron, a new parenterally active carbapenem. I. In vitro antibacterial activities [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 83–101
34.
Goto S, Katsuta M, Miyazaki S, et al. Antibacterial activity of panipenem/betamipron, a new carbapenem [in Japanese]. Chemotherapy 1991; 39 Suppl. 3
35.
Totsuka K, Kikuchi K, Shibata Y, et al. Study on postantibiotic effect (PAE) of panipenem/betamipron, a carbapenem antibiotic [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 78–82
36.
Nakashima M, Uematsu T, Kanamaru M, et al. Phase I study of panipenem/betamipron II — multiple dose study [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 265–88
37.
Nakashima M, Uematsu T, Kanamaru M, et al. Phase I study of panipenem/betamipron I — single dose study [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 242–64
38.
Fujii R, Abe T, Tajima T, et al. Overall clinical evaluation of panipenem/betamipron against infections in pediatric field [in Japanese]. Jpn J Antibiot 1992 Feb; 45(2): 208–27PubMed
39.
Aoki N, Usuda Y, Koda Y, et al. Clinical pharmacology and efficacy of panipenem/betamipron [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 372–84
40.
Kurata K. Investigation of panipenem/betamipron levels in sera and various tissues in patients of orthopedic surgery [in Japanese]. Jpn J Antibiot 1992 Feb; 45(2): 155–9PubMed
41.
Suzuki K, Horiba M, Naide Y, et al. Clinical study on panipenem/betamipron in bacterial prostatitis [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 773–7
42.
Yamamoto T, Yasuda J, Iwasaku K, et al. Basic and clinical studies on panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 636–46
43.
Yamanaka M, Miyagi E, Ooyama T, et al. Fundamental and clinical studies on panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 628–35
44.
Ishikawa M, Ishikawa M, Shimizu T, et al. Fundamental and clinical studies of panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 609–14
45.
Tanimura H, Ochiai M, Sugimoto Y, et al. Tissue concentrations and clinical efficacy of panipenem/betamipron in surgical infections [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 585–95
46.
Yura J, Shinagawa N, Ishikawa S, et al. Fundamental and clinical studies of panipenem/betamipron in surgery [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 557–71
47.
Takahashi A, Takasugi M, Utsunomiya Y, et al. Laboratory and clinical evaluation of panipenem/betamipron, a new carbapenem antibiotic [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 428–40
48.
Takagi S, Maeda H, Goto K, et al. Fundamental and clinical studies on panipenem/betamipron in urology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 484–93
49.
Naganuma H, Hirouchi Y, Kawahara Y, et al. Nephroprotective effect and its mechanism of betamipron (2) — relationships of renal excretion [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 178–89
50.
Ohashi A, Togawa A, Hishikawa A, et al. Pharmacokinetic study on panipenem/betamipron in patients with end-stage renal disease [in Japanese]. Jpn J Clin Pharmacol Ther 2003; 34(1): 17S–8SCrossRef
51.
Nagai K, Shimizu T, Togo A, et al. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron [letter]; [in Japanese]. J Antimicrob Chemother 1997 Feb; 39(2): 295–6PubMedCrossRef
52.
Yamagata T, Momoi MY, Murai K, et al. Panipenem-betamipron and decreases in serum valproic acid concentration. Ther Drug Monit 1998 Aug; 20(4): 396–400PubMedCrossRef
53.
Yamamura N, Imura K, Naganuma H, et al. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. Drug Metab Dispos 1999 Jun; 27(6): 724–30PubMed
54.
Kojima S, Nadai M, Kitaichi K, et al. Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. Antimicrob Agents Chemother 1998 Dec; 42(12): 3136–40PubMed
55.
Torii M, Takiguchi Y, Izumi M, et al. Carbapenem antibiotics inhibit valproic acid transport in Caco-2 cell monolayers. Int J Pharm 2002 Feb 21; 233(1–2): 253-6PubMedCrossRef
56.
Shimada J, Hori S, Kanemitsu K, et al. A comparative study on the convulsant activity of carbapenems and beta-lactams. Drugs Exp Clin Res 1992; 18(9): 377–81PubMed
57.
Sunagawa M, Matsumura H, Sumita Y, et al. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J Antibiot (Tokyo) 1995 May; 48(5): 408–16CrossRef
58.
Kurihara A, Hisaoka M, Mikuni N, et al. Neurotoxicity of panipenem/betamipron, a new carbapenem, in rabbits: correlation to concentration in central nervous system. J Pharmacobiodyn 1992 Jul; 15(7): 325–32PubMedCrossRef
59.
Kobayashi Y, Kanishi Y, Noda S, et al. Effectiveness of panipenem/betamipron for infections in gynecological cancer patients [abstract no. P337]. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 114
60.
Nakamura J, Fujita K, Okimoto N, et al. The study of a combination therapy of panipenem/betamipron (PAP/BP) and clindamycin (CLDM) for treatment of respiratory tract infections in elderly patients [abstract no. 3337]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, 105
61.
Ishioka T. Comparative evaluation of panipenam/betamipron and ofloxacin on urinary tract infection in the elderly [abstract no. W128]. First European Congress of Chemotherapy; 1996 May 14; Glasgow
62.
Ishioka T. Comparative evaluation of panipenem/betamipron and piperacillin on urinary tract infection in the elderly [abstract no. 114.025]. 7th International Congress for Infectious Diseases; 1996 Jun 10; Hong Kong, 300
63.
Hara K, Hiraga Y, Omichi M, et al. A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia [in Japanese]. Chemotherapy 1992; 40(4): 509–31
64.
Hara K, Kouno S KH, Takebe K, et al. A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections [in Japanese]. Chemotherapy 1992; 40(5): 613–37
65.
Kumazawa J, Matsumoto T, Kumamoto Y, et al. Phase III comparative clinical trial of panipenem/betamipron (PAPM/ BP) with imipenem/cilastatin sodium (IPM/CS) in complicated urinary tract infections [in Japanese]. Nishinihon J Urol 1992; 54(2): 254–71
66.
Hara K, Kohno S, Koga H, et al. Dose finding study on panipenem/betamipron in bacterial pneumonia [in Japanese]. Chemotherapy 1992; 40(3): 348–66
67.
Matsumoto T, Ogata N, Mizunoe Y, et al. Fundamental and clinical studies of panipenem/betamipron in the urological field [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 504–11
68.
Inatsuchi H, Masuda A, Arihara K, et al. Fundamental and clinical studies on panipenem/betamipron in urology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 469–75
69.
Chimura T, Oda T, Saito N, et al. Change of cytokines and clinical efficacy of panipenem/betamipron in obstetric and gynecological infections. Yamagata Study Group of Panipenem/Betamipron in Obstetric and Gynecological Infections [in Japanese]. Jpn J Antibiot 1998 Jan; 51(1): 37–45
70.
Hirabayashi K, Okada E. Clinical study on panipenem/ betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 810–3
71.
Manzai M, Ikuta K, Nakaya T, et al. Panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 807–9
72.
Chimura T, Tezuka N, Oda T, et al. Panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 800–3
73.
Cho N, Fukunaga K, Kunii K. Pharmacokinetics and clinical studies of panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 615–21
74.
Tsuyuki K, Arisawa Y, Yokoyama I, et al. Studies on the efficacy and safety of panipenem/betamipron in infections in surgical domain and the safety when mixed with lactate containing infusion [in Japanese]. Jpn J Antibiot 1992 Feb; 45(2): 188–96PubMed
75.
Nakayama I, Yamaji E, Kawamura H, et al. Study on surgical infections, especially intra-abdominal infections, postoperative infections, and skin and soft tissue infections: clinical application of panipenem/betamipron, a new carbapenem antibiotic for injection [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 534–51
76.
Shibuya Y, Kitamura S, Tani G, et al. Evaluation of panipenem/ betamipron (PAPM/BP) in pneumonia in elderly patients. J Infect Chemother 2002 Jun; 8(2): 151–4PubMedCrossRef
77.
Goto H, Inamatsu T, Sano Y, et al. Evaluation of a multi-hospital cooperative study on the efficacy and safety of panipenem/betamipron (PAPM/BP) on elderly patients of respiratory infections [in Japanese]. Kansenshogaku Zasshi 1999 Jan; 73(1): 43–52PubMed
78.
Shimada K, Goto H, Inamatsu T, et al. Efficacy and safety of panipenem/betamipron in respiratory infection of aged people [abstract no. 3333]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, 104
79.
Kato T, Goshima T, Akita H, et al. Clinical and bacteriological studies on panipenem/betamipron in pediatrics. Kanagawa Research Group for Infectious Diseases of Children [in Japanese]. Jpn J Antibiot 1998 Apr; 51(4): 286–97
80.
Anonymous. Discussion on the safety of panipenem/betamipron according to postmarketing surveillance [in Japanese]. Jpn J Chemother 1999; 47 (7): 396–410
81.
Katsuki K, Shinohara K, Yamada T. A case of fatal seizure and unconsciousness caused by panipenem/betamipron [in Japanese]. Kansenshogaku Zasshi 1998 Jun; 72(6): 651–3PubMed
Metadata
Title
Panipenem/Betamipron
Authors
Karen L. Goa
Stuart Noble
Publication date
01-05-2003
Publisher
Springer International Publishing
Published in
Drugs / Issue 9/2003
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200363090-00005

Other articles of this Issue 9/2003

Drugs 9/2003 Go to the issue

Therapy In Practice

Optimising Postoperative Pain Management in the Ambulatory Patient

Adis Drug Profile

Panipenem/Betamipron

Review Article

Statin Treatment and Progression of Atherosclerotic Plaque Burden

Adis Drug Profile

Panipenem/Betamipron

Leading Article

The Role of Fish Oils in the Treatment of Rheumatoid Arthritis

Review Article

New Developments in the Treatment of Functional Dyspepsia